| Summary of Revision to Company's Previous Unaudited Quarterly Financial Statements |
The impact of this revision to the Company’s previously furnished unaudited interim financial statements for the three and six months ended June 30, 2023 and for the three and nine months ended September 30, 2023 is reflected in the following tables:
BIOLASE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, 2023 |
|
|
|
As Previously Reported |
|
|
Adjustment |
|
|
As adjusted |
|
|
|
(Unaudited) |
|
Net loss |
|
$ |
(4,868 |
) |
|
$ |
— |
|
|
$ |
(4,868 |
) |
Deemed dividend on convertible preferred stock |
|
|
— |
|
|
|
(9,377 |
) |
|
|
(9,377 |
) |
Net loss attributable to common stockholders |
|
$ |
(4,868 |
) |
|
$ |
(9,377 |
) |
|
$ |
(14,245 |
) |
|
|
|
|
|
|
|
|
|
|
Net loss per share attributable to common stockholders: |
|
|
|
|
|
|
|
|
|
Basic and Diluted |
|
$ |
(8.93 |
) |
|
$ |
— |
|
|
$ |
(26.14 |
) |
Shares used in the calculation of net loss per share: |
|
|
|
|
|
|
|
|
|
Basic and Diluted |
|
|
545 |
|
|
|
— |
|
|
|
545 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, 2023 |
|
|
|
As Previously Reported |
|
|
Adjustment |
|
|
As adjusted |
|
|
|
(Unaudited) |
|
Net loss |
|
$ |
(10,717 |
) |
|
$ |
— |
|
|
$ |
(10,717 |
) |
Deemed dividend on convertible preferred stock |
|
|
— |
|
|
|
(9,377 |
) |
|
|
(9,377 |
) |
Net loss attributable to common stockholders |
|
$ |
(10,717 |
) |
|
$ |
(9,377 |
) |
|
$ |
(20,094 |
) |
|
|
|
|
|
|
|
|
|
|
Net loss per share attributable to common stockholders: |
|
|
|
|
|
|
|
|
|
Basic and Diluted |
|
$ |
(24.52 |
) |
|
$ |
— |
|
|
$ |
(45.98 |
) |
Shares used in the calculation of net loss per share: |
|
|
|
|
|
|
|
|
|
Basic and Diluted |
|
|
437 |
|
|
|
— |
|
|
|
437 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, 2023 |
|
|
|
As Previously Reported |
|
|
Adjustment |
|
|
As adjusted |
|
|
|
(Unaudited) |
|
Net loss |
|
$ |
(4,589 |
) |
|
$ |
— |
|
|
$ |
(4,589 |
) |
Deemed dividend on convertible preferred stock |
|
|
— |
|
|
|
(7,610 |
) |
|
|
(7,610 |
) |
Net loss attributable to common stockholders |
|
$ |
(4,589 |
) |
|
$ |
(7,610 |
) |
|
$ |
(12,199 |
) |
|
|
|
|
|
|
|
|
|
|
Net loss per share attributable to common stockholders: |
|
|
|
|
|
|
|
|
|
Basic and Diluted |
|
$ |
(3.89 |
) |
|
$ |
— |
|
|
$ |
(10.35 |
) |
Shares used in the calculation of net loss per share: |
|
|
|
|
|
|
|
|
|
Basic and Diluted |
|
|
1,179 |
|
|
|
— |
|
|
|
1,179 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, 2023 |
|
|
|
As Previously Reported |
|
|
Adjustment |
|
|
As adjusted |
|
|
|
(Unaudited) |
|
Net loss |
|
$ |
(15,306 |
) |
|
$ |
— |
|
|
$ |
(15,306 |
) |
Deemed dividend on convertible preferred stock |
|
|
— |
|
|
|
(16,987 |
) |
|
|
(16,987 |
) |
Net loss attributable to common stockholders |
|
$ |
(15,306 |
) |
|
$ |
(16,987 |
) |
|
$ |
(32,293 |
) |
|
|
|
|
|
|
|
|
|
|
Net loss per share attributable to common stockholders: |
|
|
|
|
|
|
|
|
|
Basic and Diluted |
|
$ |
(22.28 |
) |
|
$ |
— |
|
|
$ |
(47.01 |
) |
Shares used in the calculation of net loss per share: |
|
|
|
|
|
|
|
|
|
Basic and Diluted |
|
|
687 |
|
|
|
— |
|
|
|
687 |
|
|